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Evolution pathways of IgE responses to grass and mite
allergens throughout childhood
Adnan Custovic, MD, PhD,a* Hans-Joachim Sonntag, MRes,a,b* Iain E. Buchan, MD, PhD,b Danielle Belgrave, PhD,a,b
Angela Simpson, MD, PhD,a and Mattia C. F. Prosperi, PhDa,b Manchester, United KingdomBackground: Little is known about longitudinal patterns of the
development of IgE to distinct allergen components.
Objective: We sought to investigate the evolution of IgE
responses to allergenic components of timothy grass and dust
mite during childhood.
Methods: In a population-based birth cohort (n 5 1184) we
measured IgE responses to 15 components from timothy grass
and dust mite in children with available samples at 3 time points
(ages 5, 8, and 11 years; n 5 235). We designed a nested, 2-stage
latent class analysis to identify cross-sectional sensitization
patterns at each follow-up and their longitudinal trajectories.
We then ascertained the association of longitudinal trajectories
with asthma, rhinitis, eczema, and lung function in children
with component data for at least 2 time points (n 5 534).
Results: Longitudinal latent class analysis revealed 3 grass
sensitization trajectories: (1) no/low sensitization; (2) early onset;
and (3) late onset. The early-onset trajectory was associated with
asthma and diminished lung function, and the late-onset
trajectory was associated with rhinitis. Four longitudinal
trajectories emerged formite: (1) no/low sensitization; (2) group 1
allergens; (3) group 2 allergens; and (3) complete mite
sensitization. Children in the complete mite sensitization
trajectory had the highest odds ratios (ORs) for asthma (OR, 7.15;
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http://dx.doi.org/10.1016/j.jaci.2015.03.041associatedwith comorbid asthma, rhinitis, and eczema (OR, 5.91;
95%CI, 2.01-17.37). Among children with wheezing, those in the
complete mite sensitization trajectory (but not other longitudinal
mite trajectories) had significantly higher risk of severe
exacerbations (OR, 3.39; 95% CI, 1.62-6.67).
Conclusions: The nature of developmental longitudinal
trajectories of IgE responses differed between grass and mite
allergen components, with temporal differences (early vs late
onset) dominant in grass and diverging patterns of IgE
responses (group 1 allergens, group 2 allergens, or both) in mite.
Different longitudinal patterns bear different associations with
clinical outcomes, which varied by allergen. (J Allergy Clin
Immunol 2015;136:1645-52.)
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Atopic sensitization is a strong risk factor for asthma,
rhinoconjunctivitis, and eczema.1 Sensitization is traditionally
defined as a positive allergen-specific serum IgE (sIgE) result or
a positive skin prick test response using extracts from whole
allergen sources.2 These standard allergy tests have high sensi-
tivity but relatively low specificity, and a positive test result
does not confirm clinical reactivity on allergen exposure.1 We
have previously shown that quantification (ie, using the level of
sIgE antibodies or the size of skin prick test–induced wheal)
can increase the specificity (both in terms of diagnostic accuracy
and the capacity to predict the persistence of symptoms),3-6 but
the problem of a significant number of false-positive test results
remains.7
One potential problem related to the use of whole allergen
extracts is that natural sources used for their preparation contain
multiple allergenic proteins (components), and each component
can contain multiple epitopes for binding IgE. Because of
homology between proteins from the same family present in
different allergen sources (eg, profilin and pathogenesis-related
class 10 proteins in plants), a positive result might reflect
reactivity to cross-reactive components rather than an indepen-
dent sensitization event.8 Consequently, interpretation of the tests
routinely available in the clinic can be challenging.7 Recent ad-
vances in biochemistry and molecular biology have led to the
isolation and characterization of numerous allergen components.
Their recombinant production facilitates the profiling of IgE reac-
tivity to individual allergens at the molecular level, and this new
approach to allergy diagnosis has been termed molecular diag-
nosis or component-resolved diagnostics (CRD).8,9 One such
emerging technology is the multiplex Immuno Solid-phase
Allergen Chip (ImmunoCAP ISAC), an in vitro diagnostic tool
that is based exclusively on allergen components. This array mea-
sures sIgE levels to more than 100 allergen components and has1645
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Recently, we have reported that machine learning modeling of
ISAC data might facilitate a more accurate assessment of allergic
diseases, showing that combinations of allergen components can
predict concomitant asthma or rhinoconjunctivitis onset with fair
sensitivity/specificity.11 Hatzler et al12 have used the CRD
approach to demonstrate that IgE responses to timothy grass dur-
ing childhood increase in molecular complexity over time
through ‘‘molecular spreading,’’ in which sensitization to a
‘‘lead allergen’’ (Phl p 1) precedes a characteristic sequence of
further increase in the number of recognized molecules.
We hypothesize that there is an underlying complexity and
heterogeneity in the longitudinal patterns of the development of
component-specific IgE responses within individual patients and
that different longitudinal patterns of IgE responses to distinct
allergen components within the whole allergen source might be
associated with different allergic diseases. To address our
hypotheses, we conducted longitudinal analysis of ImmunoCAP
ISAC CRD data, focusing on timothy grass and dust mite as
examples of seasonal and perennial allergens linked to expression
of rhinitis and asthma, respectively. We designed a nested latent
class probabilistic modeling approach to allow the discovery of
such a latent structure within the data that reflects the individual
life course, with the aim of investigating the evolution of IgE
profiles during childhood. These sensitization trajectories were
then related to asthma, rhinitis, and eczema. We carried out the
study among participants in a population-based birth cohort, in
whom sIgE levels and detailed clinical assessment were ascer-
tained at 5 follow-ups during the first 11 years of life.13METHODS
Study population
The Manchester Asthma and Allergy Study (MAAS) is a population-based
birth cohort (registration: ISRCTN72673620).13,14 MAAS was approved
by the local research ethics committee; parents provided written informed
consent.Data sources
Clinical follow-up. Participants attended follow-ups at ages 1, 3, 5,
8, and 11 years. Blood samples were collected from children who gave assent
for venipuncture. Validated questionnaires were interviewer administered to
collect information on parentally reported symptoms, physician-diagnosed
diseases, and treatment received. At age 11 years, we measured lung function
using spirometry and airway reactivity in a 5-step protocol using quadrupling
doses of methacholine.15 The fraction of exhaled nitric oxide (eNO) was
measured according to the American Thoracic Society (ATS)/European Res-
piratory Society recommendations as a marker of airway inflammation.16Medical records data. We extracted data from children’s primary
care medical records, including oral corticosteroid prescriptions, emergency
department admissions, and asthma/wheeze-related hospitalizations.17Definition of variables
We defined clinical outcomes from the data collected at age 11 years.
Severe asthma/wheeze exacerbations during childhood were ascertained from
medical records data.
Current wheezewas defined as a positive answer to the following question:
‘‘Has your child had wheezing or whistling in the chest in the last 12 months?’’
Current asthma was defined as the presence of any 2 of the 3 features: (1) cur-
rent wheeze; (2) current use of asthmamedication; and (3) physician-diagnosed
asthma ever. Current rhinitis was defined as a positive answer to the following
question: ‘‘In the past 12months, has your child had a problemwith sneezing or
a runny or blocked nose when he/she did not have a cold or the flu?’’18 Current
eczema was defined as a positive answer to the following question: ‘‘Has your
child had an itchy rash that comes and goes in the last 12 months?’’ Severe
wheeze/asthma exacerbation was defined as receipt of oral corticosteroids
for at least 3 days or admission to the hospital or emergency department visit
because of asthma/wheeze requiring oral steroids.19,20 FEV1 was expressed
as percent predicted21; we also recorded FEV1/forced vital capacity (FVC) ra-
tio. Children were categorized as having airway hyperreactivity after a 20%
decrease in FEV1 by the final stage of the challenge. We calculated the dose-
response ratio22 to include all evaluable data as a continuous variable.CRD
ImmunoCAP ISAC (Thermo Fisher Scientific, Uppsala, Sweden) was used
to measure sIgE levels to 112 allergenic molecules. IgE antibodies to 15
allergen components were considered in this study: 8 timothy grass (Phleum
pratense) components (Phl p 1, 2, 4, 5, 6, 7, 11, and 12) and 7 mite (Derma-
tophagoides farinae, Dermatophagoides pteronyssinus, Blomia tropicalis,
and the storage mite Lepidoglyphus destructor) components (Der f 1, 2, Der
p 1, Der p 2, Der p 10, Lep d 2, and Blo t 5). The level of component-
specific IgE antibodies was reported in ISAC standardized units (ISU). We
categorized the raw data into 4 sIgE semiquantitative discrete groups, accord-
ing to the manufacturer’s guidelines: no (<0.3 ISU), low (0.3-1 ISU), medium
(1-15 ISU), and high (>15 ISU) sensitization.Statistical methods
We designed a nested, 2-stage latent class analysis (LCA) to identify cross-
sectional sensitization patterns and their longitudinal time trajectories. LCA is
a statistical method for finding subgroups (ie, latent classes or clusters) of
related cases from multivariate discrete data based on the patterns of their
associated variables. In the current study LCA enabled exploration as to
whether in our study population there are subgroups into which study
participants cluster based on the cross-sectional and longitudinal patterns of
sIgE responses to different allergen components (ie, 8 components for timothy
grass and 7 components for mite).
Fig 1 shows a schematic description of our nested modeling approach. We
first applied LCA on sIgE data at each time point to identify cross-sectional
sensitization classes and then used such inferred class membership in a further
LCA on the longitudinal data to analyze the evolution of IgE profiles over
time. Thus a first-level LCA inferred cross-sectional sensitization classes at
each of the 3 time points (sensitization profiles at ages 5, 8, and 11 years);
we then proceeded to perform a second-level LCA to establish longitudinal
time trajectories of these sensitization profiles (ie, sensitization trajectories).
LCAwas performedwith R software (http://www.r-project.org/). Formore de-
tails on statistical methods, please see theMethods section in this article’s On-
line Repository at www.jacionline.org.
To make full use of the ISAC data available for regression analysis, we
allocated children who had specific IgE measurements taken at 2 of 3 time
points to the trajectory that had the most corresponding combinations of class
memberships in it. We related trajectories to clinical outcomes through
logistic regression.23,24
FIG 1. Use of nested LCA to infer sensitization patterns and time trajectories. At 3 time points (Age I, Age II,
and Age III), sensitizations to 3 allergens (a1, a2, and a3) are measured in the population. The prevalence of
these allergens in the study population per each time point is shown below each age landmark outside the
boxes. When LCA is applied, at each time point, 1 or more allergen patterns can be found. The square boxes
below each age landmark represent the latent space and include sensitization patterns (classes c1-c4) found
at each time point. If the same allergen patterns are found at different ages, they are labeled consistently.
Subjects can be assigned to a particular class at each time point by looking at their allergen profiles. After
this first LCA, the prevalence of classes in the population at each time point can be calculated (not shown for
simplicity). A second-stage LCA can be applied to the classes across time points to identify longitudinal pat-
terns of transition/stasis among classes. These are called time trajectories and are shown as lines that con-
nect one class to another in a subsequent age point (t1-t4). Trajectories will have assigned probabilities as
well (not shown).
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Participant flow and demographic data
Of 1184 children prenatally enrolled, ImmunoCAP ISAC data
were available for 226 children at age 1 year, 248 at age 3 years,
588 at age 5 years, 543 at age 8 years, and 461 at age 11 years.
Data at ages 1 and 3 years were very sparse (eg, only 5 children
were sensitized to any of the timothy grass allergens at age 1
year). Therefore we made an a priori decision to use data from
ages 5, 8, and 11 years in the analysis. We inferred longitudinal
trajectories among 235 children who had ISAC data at all 3
time points and allocated trajectories to investigate their clinical
relevance among 534 children with ISAC data from at least 2
time points. Demographic characteristics are summarized in
Table I, with details on by-age prevalence of sensitizations to spe-
cific components shown in Table E1 in this article’s Online Re-
pository at www.jacionline.org. Maternal atopy and asthma
were more common among children without ISAC data; there
were no significant differences in demographic data or clinical
outcomes between children included and those excluded from
this analysis (Table I).Cross-sectional sensitization profiles
Timothy grass. Three cross-sectional classes were identified
at age 5 years, and 4 classes were identified at ages 8 and 11 years
(see Fig E1 in this article’s Online Repository at www.jacionline.
org). The first 3 classes were virtually identical across all ages,whereas the fourth class emerged at ages 8 and 11 years. On the
basis of the number of allergen components towhich sensitization
occurred and on the levels of component-specific IgE antibodies,
we qualitatively labeled the 4 cross-sectional sensitization pro-
files as no, mild, moderate, and severe sensitization. The mild
sensitization profile was characterized by a greater than 40%
probability of IgE antibody response to Phl p 1, 4, and 5 (but
not other components) at all ages, with most children belonging
to this profile having low or medium sIgE levels. In contrast, chil-
dren in the severe sensitization profile at age 11 years had greater
than 40% probability of IgE response to all 8 components, with a
majority of sIgEs having medium or high levels (see Fig E1, C).
The proportion of children within each of the sensitization pro-
files at different ages is presented in Table E2 in this article’s On-
line Repository at www.jacionline.org. With increasing age, there
was a shift toward a higher proportion of children belonging to
more severe sensitization profiles.
Dust mite. A 5-class model was optimal at each of the 3 time
points (see Fig E2 in this article’s Online Repository at www.
jacionline.org). On the basis of the allergen components that eli-
cited IgE responses and the levels of component-specific IgE an-
tibodies, we qualitatively labeled the profiles as no sensitization,
group 1 sensitization, group 2 sensitization, complete moderate
sensitization, and complete high sensitization. It is noteworthy
that at each time point, we found that some children were sensi-
tized to 1 allergen component group only. The proportion of chil-
dren within each of the sensitization profiles at different ages is
FIG 2. Latent classes inferred for timothy grass allergens to identify trajectories of cross-sectional
sensitization classes over time.
TABLE I. Population characteristics of children with or without ISAC data available for at least 2 time points or all 3 ages (5, 8, and
11 years)
ISAC data on >_2 time points
(n 5 534), no. (%)
ISAC data, ages 5, 8, and 11 y
(n 5 235), no. (%)
No ISAC data
(n 5 650), no. (%) P value
Sex (male) 292/534 (54.7) 132/235 (56.1) 350/650 (53.9) .774
Older siblings 309/533 (58.0) 134/235 (57.0) 290/543 (53.4) .132
Maternal smoking (pregnancy) 62/530 (11.7) 29/235 (12.3) 57/495 (11.5) .927
Maternal asthma 87/534 (16.3) 41/235 (17.5) 148/650 (22.8) .005
Paternal asthma 81/534 (15.2) 32/235 (13.6) 82/648 (12.7) .212
Maternal atopy 292/522 (55.9) 124/230 (53.9) 390/624 (62.5) .024
Paternal atopy 328/518 (63.3) 136/229 (59.4) 388/619 (62.7) .824
Sensitization (skin prick test), age 3 y 102/478 (21.3) 40/215 (18.6) 123/505 (24.4) .260
Sensitization (skin prick test), age 5 y 149/512 (29.1) 57/232 (24.6) 145/451 (32.2) .305
Sensitization (skin prick test), age 8 y 165/520 (31.7) 63/231 (27.3) 149/407 (36.6) .119
Sensitization (skin prick test), age 11 y 161/470 (34.3) 70/232 (30.2) 119/325 (36.6) .493
Current asthma, age 11 y 93/498 (18.7) 31/200 (15.5) 97/416 (23.3) .085
FEV1 (% predicted), age 11 y 98.92 (97.87-99.96) 99.54 (98.08-101.01) 97.60 (96.31-98.90) .120
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jacionline.org. In contrast to timothy grass, there was little evi-
dence for a shift toward a higher proportion of children belonging
to the severe sensitization profile with increasing age.Longitudinal sensitization trajectories
Timothy grass. We identified 3 sensitization trajectories in
the longitudinal LCA. Cross-sectional sensitization profiles
within each of the longitudinal sensitization trajectories at
different ages are shown in Fig 2. On the basis of their character-
istics, we qualitatively labeled them as follows: no/low grass
sensitization trajectory (82.1%), late-onset trajectory (14.9%),
and early-onset trajectory (3.0%). Fig E3 in this article’s Online
Repository at www.jacionline.org shows sIgE levels to individual
allergenic components in different trajectories and their evolution
over time. Children in the early-onset trajectory had high levels of
sIgE to grass allergens at age 5 years, whereas those in the late-
onset trajectory had IgE responses between ages 5 and 11 years.
However, the progression of individual component responses ap-
peared similar in the early- and late-onset trajectories, following
the sequence of Phl p 1/5/ Phl p 2/4/6/ Phl p 7/11/12. IgE
antibody levels specific to the components that induced sensitiza-
tion early on increased in concentration with increasing age.
Dust mite. We identified 4 sensitization trajectories in the
longitudinal LCA. Cross-sectional sensitization profiles withineach of the longitudinal sensitization trajectories at different ages
are shown in Fig 3. We qualitatively labeled these as follows: no/
low mite sensitization trajectory (83.8%), group 1 allergens tra-
jectory (4.3%), group 2 allergens trajectory (3.8%), and complete
mite sensitization trajectory (8.1%). Fig E4 in this article’s Online
Repository at www.jacionline.org shows sIgE levels to individual
allergenic components in different trajectories and their evolution
over time. High levels of sIgE antibodies at any time point were
observed only for Der f 1/Der p 1 and Der f 2/Der p 2, and the tra-
jectories suggested that children might either have an IgE
response to only one of these 2 allergen groups or become cosen-
sitized to both at an early age; very rarely could a spreading of IgE
response to the other allergen group be observed.Association between longitudinal sensitization
trajectories and clinical outcomes
Thereweremarked differences between different trajectories in
relation to asthma, rhinitis, eczema, lung function, airway hyper-
reactivity, and airway inflammation. Table II lists odds ratios
(ORs) relating to the incidence of clinical outcomes for the various
timothy grass and dust mite trajectories, whereas Table III
provides summary statistics for lung function measurements.
Timothy grass sensitization trajectories. The early-
onset trajectory was associated with a significantly higher risk of
asthma, comorbidity of allergic diseases (asthma, rhinitis, and
FIG 3. Latent classes inferred for house dust mite allergens to identify trajectories of cross-sectional
sensitization classes over time.
TABLE II. Relationship between longitudinal trajectories for timothy grass and house dust mite allergens in relation to clinical
outcomes of asthma, rhinitis, and eczema
Timothy grass longitudinal
sensitization trajectories Dust mite longitudinal sensitization trajectories
Late onset (n 5 97),
OR (95% CI), P value
Early onset (n 5 23),
OR (95% CI), P value
Group 1 allergens
(n 5 23), OR
(95% CI), P value
Group 2 allergens
(n 5 22), OR
(95% CI), P value
Complete mite
sensitization (n 5 54),
OR (95% CI), P value
Positive methacholine
challenge
1.68 (0.97-2.91), .062 2.86 (0.99-8.28), .052 6.90 (2.17-21.97), .001 2.30 (0.84-6.32), .106 6.44 (3.00-13.82), <.001
Current wheeze 1.31 (0.73-2.35), .364 3.63 (1.49-8.86), .005 4.24 (1.69-10.63), .002 4.24 (1.69-10.63), .002 7.13 (3.81-13.34), <.001
Current asthma 1.53 (0.85-2.76), .158 6.20 (2.56-15.01), <.001 4.60 (1.83-11.56), .001 3.02 (1.12-8.10), .029 7.15 (3.80-13.44), <.001
Current rhinitis 5.84 (3.59-9.50), <.001 11.84 (4.25-33.01), <.001 6.11 (2.42-15.38), <.001 2.37 (0.99-5.66), .051 4.07 (2.23-7.42), <.001
Current eczema 1.15 (0.64-2.08), .637 3.71 (1.50-9.18), .004 3.21 (1.28-8.06), .013 0.82 (0.24-2.87), .761 2.17 (1.12-4.20), .021
Current asthma, rhinitis,
and eczema
2.20 (0.65-7.46), .207 17.91 (5.55-57.74), <.001 4.43 (0.90-21.88), .068 2.11 (0.26-17.45), .488 5.91 (2.01-17.37), .001
Severe asthma exacerbation
ever among wheezy
children
1.96 (1.03-3.74), .041 3.91 (1.39-11.02), .010 1.82 (0.68-4.89), .233 1.30 (0.44-3.88), .636 3.29 (1.62-6.67), .001
ORs, 95% CIs, and P values are from univariate logistic regression. The reference category is the no/low grass sensitization trajectory.
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reactive airways compared with the late-onset and no/low grass
sensitization trajectories (Tables II and III). The late-onset trajec-
tory was not significantly associated with asthma, but there was a
strong association with rhinitis (Table II).
Among children with a history of wheezing, both children in
the early-onset and those in the late-onset trajectories had notably
higher risk of severe asthma exacerbations during childhood
(Table II); however, themagnitude of risk was significantly higher
in the early-onset trajectory (ORs of 3.91 [95% CI, 1.39-11.02;
P 5 .01] and 1.96 [95% CI, 1.03-3.74; P 5 .04]), early-onset
and late-onset trajectories, respectively.
Dust mite sensitization trajectories. Both the group 1
allergens and complete mite sensitization trajectories were
strongly associated with asthma, eczema, and rhinitis, but the
children in the complete mite sensitization trajectory had the
highest ORs for asthma (OR, 7.15; 95% CI, 3.80-13.44) and were
the only group significantly associated with asthma, with rhinitis
and eczema as comorbidities (OR, 5.91; 95% CI, 2.01-17.37;
Table II). Children belonging to the group 2 allergens trajectory
generally had lower odds of clinical symptoms, except for a sig-
nificant association with asthma. Children in the complete mite
sensitization trajectory had significantly higher eNO levels (P <
.05) compared with those in the group 1 allergens and group 2 al-
lergens trajectories (Table III).
Among children with a history of wheezing, those in the
complete mite sensitization trajectory (but not in other mite
longitudinal trajectories) had significantly higher risk of severeasthma exacerbations during childhood (OR, 3.29; 95% CI,
1.62-6.67).DISCUSSION
Key findings
Our findings suggest that the nature of the development of IgE
responses during childhood to multiple allergen components
differs between timothy grass and dust mite allergens. Our data
indicate that IgE reactivity profiles to timothy grass components
diversify and increase in concentration and molecular heteroge-
neity over time, confirming the ‘‘molecular spreading’’ hypoth-
esis.12 We have shown that this process can be initiated at
different times in childhood, giving rise to an early-onset or
late-onset longitudinal trajectory. Different pathways emerged
for dust mite components in that the dominant longitudinal
pattern of progression from individual component responses to
multiple sensitization did not emerge. Instead, children either re-
mained firmly sensitized to one of the component groups (group 1
or 2 allergens) throughout childhood or there was a cosensitiza-
tion to these major allergen groups, with little progression from
one developmental pathway to the other. Thus for dust mite, the
key discriminating factor appears to be the panel of allergen com-
ponents that elicit an IgE response, rather than temporal factors
(as is the case for grass).
We demonstrated that different longitudinal patterns of IgE
responses to grass and mite allergen components during child-
hood bear different associations with clinical outcomes. For
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1650 CUSTOVIC ET ALtimothy grass, the early-onset longitudinal trajectory was predic-
tive of asthma, rhinitis, and eczema (as well as being associated
with diminished lung function in school age), whereas the late-
onset trajectory was significantly associated with rhinitis. For dust
mite, children in the completemite sensitization trajectory had the
highest risk of asthma and significantly higher eNO levels
compared with those in all other trajectories. Children in the
group 2 allergens trajectory tended to have a lower risk of clinical
disease compared with those in the group 1 allergens or complete
mite sensitization trajectories. Finally, the grass early-onset and
complete mite sensitization trajectories were the only longitudi-
nal trajectories significantly associated with asthma with comor-
bid rhinitis and eczema; furthermore, among children with a
history of wheezing, those belonging to these 2 longitudinal
trajectories had markedly increased risk of severe exacerbations
during childhood. The risk of exacerbation was also increased
among children in the late-onset grass trajectory. However, we
note that our results need to be interpretedwith caution and should
not be used to make definitive conclusions given the relatively
modest sample size and wide CIs we observed when we examined
the relationship between longitudinal trajectories and various
clinical outcomes.
Limitations
There are several potentially important mite allergens that are
not included on the ISAC chip. We cannot exclude the
possibility that Der f 1/Der p 1 and Der f 2/Der p 2 might
both act as lead allergens in a molecular spreading process that
involves such allergens. For example, previous studies have
demonstrated that although the majority of IgE binding to D
pteronyssinus allergens was accounted for by Der p 1 and Der
p 2 across a large range of allergic subjects, a further 30%
was due to Der p 4, Der p 5, and Der p 7 in equal amounts, es-
tablishing these as midpotency allergens.25 Hence the combina-
tion of mite allergen components present on the ISAC chip
might not be optimal for the investigation of molecular
spreading. However, even if molecular spreading does occur,
based on our data, it would be expected to follow at least 2
fundamentally different pathways characterized predominantly
by IgE responses to group 1 or group 2 allergen components.
Another limitation relates to the availability of data in earlier
life. Although ISAC data were available for 226 children at age 1
year and 248 children at age 3 years, this added little information
because only 5 children were sensitized to any of the timothy grass
allergens at age 1 year and only 6 children were sensitized to at
least 1 of the dust mite allergens. However, we cannot exclude a
possibility that the information of component IgE responses in
early life would be valuable in a much larger sample. We
ascertained sensitization trajectories in a subpopulation on children
who attended follow-ups at ages 5, 8, and 11 years and gave assent
for venipuncture and cannot unequivocally exclude the possibility
of bias. However, it is unlikely that this would have affected the
allocation to different cross-sectional sensitization profiles or
longitudinal sensitization trajectories.
Interpretation
Atopic subjects frequently experience multiple sensitization
events as time progresses.26 Using a nested LCA model, we
identified a clear diversification of the IgE responses to timothy
grass allergens over time, which is suggestive of increasing
J ALLERGY CLIN IMMUNOL
VOLUME 136, NUMBER 6
CUSTOVIC ET AL 1651molecular heterogeneity as time progresses. This is reflected in
the fact that a 3-class model best captured the underlying struc-
ture of the data at age 5 years, whereas 4 classes were more
appropriate for ages 8 and 11 years. In addition to this cross-
sectional observation, our longitudinal analysis confirmed the
molecular spreading for timothy grass. However, it is of note
that although there were differences in the time of onset of
IgE reactivity, the 2 major grass longitudinal sensitization tra-
jectories showed a similar pattern of progression of individual
component responses: after initial sensitization to the lead aller-
gens Phl p 1 and 5, one can observe additional IgE responses to
Phl p 2, 4, and 6 at later times, with some children also having
sIgE to Phl p 7, 11, and 12 thereafter.
Recently, by analyzing longitudinal skin prick test and sIgE
data to whole allergen extracts collected from birth to school age
in our birth cohort, we identified that atopy can encompass several
different subtypes characterized by a unique pattern of response,
both in terms of allergens and time course.27 These subtypes
differed in their associations with clinical outcomes; one of these
classes (characterized by early responses to multiple allergens)
was strongly associated with asthma. These findings were
recently validated in an independent birth cohort.28 Although
these results highlight the deficiencies of the current interpreta-
tion of allergy tests, the above approach cannot as yet be applied
in the clinic because it is reliant on the availability of longitudinal
data.1 Results of the current study indicate that characterization of
atopic subtypes over time might help further elucidate the highly
divergent development of clinical symptoms among atopic chil-
dren.29,30 This is supported by our finding of the different associ-
ation between longitudinal trajectories of the component-specific
IgE and clinical outcomes. For example, for timothy grass, the
early-onset trajectory was predictive of lower airway-related clin-
ical outcomes and comparatively poorer lung function, whereas
the late-onset trajectory was predominantly associated with upper
airway disease (rhinitis). For dust mite allergens, children in the
complete mite sensitization trajectory tended to have the highest
risk for asthma (in particular with comorbidities), higher airway
inflammation (eNO), and, among asthmatic patients, higher risk
of severe exacerbations compared with those from all other longi-
tudinal trajectories.
In conclusion, our findings suggest that different longitudinal
patterns in the development of IgE responses to grass and mite
allergen components during childhood are associated with
different clinical outcomes and confirm the hypothesis that atopic
sensitization can be stratified into subtypes with a diversification
of their evolutionary pathways over time.1,27,28,31 Better resolu-
tion of such longitudinal patterns might help us better understand
the pathophysiology underlying atopic diseases and might facili-
tate the development of biomarkers of allergic disease, which can
be used for the prediction of future risk.
Clinical implications: Development of different clinical pheno-
types of allergic diseases (asthma, eczema, and rhinitis), as
well as asthma severity throughout childhood, is predicted by
the molecular nature of IgE responses to individual allergen
components.REFERENCES
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METHODS
Statistical analysis
We designed a nested, 2-stage LCA to identify sensitization trajectories.
First, we looked at each time point (5, 8, and 11 years) individually and applied
LCAwith sensitization profiles for each of the allergens as manifest variables
to reduce the data dimensionality and determine the major IgE reactivity
profiles at each age. Next, we used the class memberships inferred from the
first LCA as manifest variables in a further LCA to detect groups of children
with a similar evolution in their sensitization profiles (as shown in Fig 1).
LCA was performed by using the R software (http://www.r-project.org/)
through the package poLCAE1 with the expectation maximization algorithm
to estimate relevant parameters (with 10,000 iterations over 100 independent
runs to check convergence).E2 We determined the number of classes for each
analysis using both the Akaike information criterion and Bayesian informa-
tion criterion,E3-E5 choosing the Akaike information criterion for results re-
ported here because this provided a qualitatively better resolution at
component level. The average sensitization intensity toward allergens at
each age for the class trajectories was calculated as the mean of sensitization
categories for all children in a particular trajectory. CIs were inferred by using
bootstrappingE6 with the R package boot.E7
Lung function measurement
Children were asymptomatic at the time of assessment of lung function.
Short-actingb2-agonists werewithheld for at least 6 hours and long-acting b2-
agonists were withheld for at least 24 hours before testing.
Spirometry. Spirometry was performed at age 11 years according to
ATS guidelines by using a Lilly pneumotachograph system with animated
incentive software (Jaeger, W€urzburg, Germany). FEV1 and FVC values were
recorded, and data were expressed as FEV1 percent predicted and FEV1/FVC
ratio.
Airway hyperreactivity. At the 11-year follow-up, airway reac-
tivity was assessed bymeans of methacholine challengewith a 5-step protocol
performed according to ATS guidelines. Quadrupling doses of methacholine
(0.0625-16.0 mg/mL) were delivered to subjects through a DeVilbiss 646
nebulizer (Sunrise Medical HHG, Somerset, Pa) and a KoKo dosimeter
(Pulmonary Data Services, Doylestown, Pa) calibrated to deliver 0.009 mL/
0.6 s actuation. The predicted FEV1 was calculated, and if the measured value
was less than 1.0 L or less than 60% of predicted value, the test was not per-
formed. FEV1 was measured 30 and 90 seconds after 5 inhalations of each
dose of methacholine. The challengewas stopped when either a 20% decrease
in FEV1 was observed or the maximum methacholine concentration had been
administered.
Data from primary care medical records
We extracted all data from electronic and paper-based primary caremedical
records, including oral corticosteroid prescriptions, emergency department
admissions, and asthma/wheeze-related hospitalizations.E8 Eligible practices
were contacted and invited to participate in the study either by both postal in-
formation packs and telephone calls (general practitioner [GP] practices with
>_2 children in the study) or by post only (GP practices with a single study
participant). Data access and manual extraction were performed during ar-
ranged visits to each GP practice. A trained pediatrician extracted data from
electronic and paper-based primary care medical records, including prescrip-
tions, acute wheeze episodes, oral steroid prescriptions, and hospital admis-
sions for asthma or wheeze during the first 8 years of life. Timing, type of
visit, symptoms, indication, and prescriptions for each encounter were noted.
We calculated the child’s age in days for each event.
CRD
We categorized the raw data into 4 sIgE semiquantitative discrete groups
according to the manufacturer’s guidelines: no (<0.3 ISU), low (0.3-1 ISU),
medium (1-15 ISU), and high (>15 ISU) sensitization. Other discretization
techniques were also tested, including a binary based on the threshold of 0.3
ISU; however, our previous results showed that categorization based on the
manufacturer’s guidelines compared favorably with alternatives.E9
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FIG E1. Nested latent classes inferred for the timothy grass allergens for cross-sectional sensitization
profiles. Each class corresponds to a particular distribution of IgE categories in each allergen component
(here the probability of being highly sensitized to a specific allergen by each class is depicted). This first-
level analysis is carried out at the time points of 5 years (A), 8 years (B), and 11 years (C) of age, and resulting
classes are matched across ages based on their IgE distribution patterns.
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FIG E2. Nested latent classes inferred for dust mite allergens for cross-sectional sensitization profiles. Each
class corresponds to a particular distribution of IgE categories in each allergen component (here the
probability of being highly sensitized to a specific allergen by each class is depicted). This first-level analysis
is carried out at the time points of 5 years (A), 8 years (B), and 11 years (C) of age, and resulting classes are
matched across ages based on their IgE distribution patterns.
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FIG E3. sIgE levels to timothy grass allergens in different trajectories and
their evolution over time. Semiquantitatively discretized IgE levels have
been allocated numeric values: 0, negative; 1, low; 2, medium; and 3, high.
Bars indicate 95% bootstrap CIs around the mean for each allergen. A, No/
low grass sensitization trajectory. B, Late-onset trajectory. C, Early-onset
trajectory.
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FIG E4. sIgE levels to house dust mite allergens in different trajectories and
their evolution over time. Semiquantitatively discretized IgE levels have
been allocated numeric values: 0, negative; 1, low; 2, medium; 3, high. Bars
indicate 95% bootstrap CIs around the mean for each allergen. A, Group 1
allergens trajectory. B, Group 2 allergens trajectory. C, Complete mite
sensitization trajectory.
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TABLE E1. Prevalence of component-specific sensitizations
(semiquantitative IgE level scale) across different ages
Age Component
Sensitization
No (<0.3 ISU)
Low
(0.3-1 ISU)
Medium
(1-15 ISU)
High
(>15 ISU)
1 y Phl p 1 226 (100%) 0 (0%) 0 (0%) 0 (0%)
Phl p 2 226 (100%) 0 (0%) 0 (0%) 0 (0%)
Phl p 4 221 (97.79%) 5 (2.21%) 0 (0%) 0 (0%)
Phl p 5 226 (100%) 0 (0%) 0 (0%) 0 (0%)
Phl p 6 226 (100%) 0 (0%) 0 (0%) 0 (0%)
Phl p 7 226 (100%) 0 (0%) 0 (0%) 0 (0%)
Phl p 11 226 (100%) 0 (0%) 0 (0%) 0 (0%)
Phl p 12 226 (100%) 0 (0%) 0 (0%) 0 (0%)
Der f 1 223 (98.67%) 3 (1.33%) 0 (0%) 0 (0%)
Der f 2 224 (99.12%) 1 (0.44%) 1 (0.44%) 0 (0%)
Der p 1 224 (99.12%) 1 (0.44%) 1 (0.44%) 0 (0%)
Der p 2 223 (98.67%) 2 (0.88%) 1 (0.44%) 0 (0%)
Der p 10 226 (100%) 0 (0%) 0 (0%) 0 (0%)
Lep d 2 226 (100%) 0 (0%) 0 (0%) 0 (0%)
Blo t 5 226 (100%) 0 (0%) 0 (0%) 0 (0%)
3 y Phl p 1 219 (88.31%) 15 (6.05%) 12 (4.84%) 2 (0.81%)
Phl p 2 247 (99.6%) 1 (0.4%) 0 (0%) 0 (0%)
Phl p 4 228 (91.94%) 12 (4.84%) 8 (3.23%) 0 (0%)
Phl p 5 241 (97.18%) 3 (1.21%) 2 (0.81%) 2 (0.81%)
Phl p 6 246 (99.19%) 1 (0.4%) 1 (0.4%) 0 (0%)
Phl p 7 248 (100%) 0 (0%) 0 (0%) 0 (0%)
Phl p 11 246 (99.19%) 1 (0.4%) 1 (0.4%) 0 (0%)
Phl p 12 248 (100%) 0 (0%) 0 (0%) 0 (0%)
Der f 1 226 (91.13%) 7 (2.82%) 14 (5.65%) 1 (0.4%)
Der f 2 229 (92.34%) 5 (2.02%) 9 (3.63%) 5 (2.02%)
Der p 1 221 (89.11%) 9 (3.63%) 16 (6.45%) 2 (0.81%)
Der p 2 229 (92.34%) 5 (2.02%) 11 (4.44%) 3 (1.21%)
Der p 10 248 (100%) 0 (0%) 0 (0%) 0 (0%)
Lep d 2 248 (100%) 0 (0%) 0 (0%) 0 (0%)
Blo t 5 248 (100%) 0 (0%) 0 (0%) 0 (0%)
5 y Phl p 1 484 (82.31%) 26 (4.42%) 49 (8.33%) 29 (4.93%)
Phl p 2 561 (95.41%) 11 (1.87%) 13 (2.21%) 3 (0.51%)
Phl p 4 499 (84.86%) 37 (6.29%) 45 (7.65%) 7 (1.19%)
Phl p 5 517 (87.93%) 13 (2.21%) 29 (4.93%) 29 (4.93%)
Phl p 6 554 (94.22%) 14 (2.38%) 14 (2.38%) 6 (1.02%)
Phl p 7 584 (99.32%) 2 (0.34%) 2 (0.34%) 0 (0%)
Phl p 11 580 (98.64%) 3 (0.51%) 3 (0.51%) 2 (0.34%)
Phl p 12 584 (99.32%) 2 (0.34%) 2 (0.34%) 0 (0%)
Der f 1 513 (87.24%) 15 (2.55%) 43 (7.31%) 17 (2.89%)
Der f 2 516 (87.76%) 6 (1.02%) 26 (4.42%) 40 (6.8%)
Der p 1 506 (86.05%) 16 (2.72%) 43 (7.31%) 23 (3.91%)
Der p 2 515 (87.59%) 7 (1.19%) 24 (4.08%) 42 (7.14%)
Der p 10 585 (99.49%) 3 (0.51%) 0 (0%) 0 (0%)
Lep d 2 570 (96.94%) 6 (1.02%) 9 (1.53%) 3 (0.51%)
Blo t 5 583 (99.15%) 3 (0.51%) 1 (0.17%) 1 (0.17%)
8 y Phl p 1 425 (78.27%) 25 (4.6%) 70 (12.89%) 23 (4.24%)
Phl p 2 506 (93.19%) 7 (1.29%) 26 (4.79%) 4 (0.74%)
Phl p 4 448 (82.5%) 39 (7.18%) 49 (9.02%) 7 (1.29%)
Phl p 5 456 (83.98%) 21 (3.87%) 43 (7.92%) 23 (4.24%)
Phl p 6 505 (93%) 19 (3.5%) 18 (3.31%) 1 (0.18%)
Phl p 7 541 (99.63%) 2 (0.37%) 0 (0%) 0 (0%)
Phl p 11 528 (97.24%) 7 (1.29%) 8 (1.47%) 0 (0%)
Phl p 12 534 (98.34%) 5 (0.92%) 4 (0.74%) 0 (0%)
Der f 1 468 (86.19%) 9 (1.66%) 44 (8.1%) 22 (4.05%)
Der f 2 470 (86.56%) 7 (1.29%) 23 (4.24%) 43 (7.92%)
Der p 1 463 (85.27%) 8 (1.47%) 44 (8.1%) 28 (5.16%)
Der p 2 466 (85.82%) 7 (1.29%) 25 (4.6%) 45 (8.29%)
Der p 10 539 (99.26%) 1 (0.18%) 2 (0.37%) 1 (0.18%)
Lep d 2 525 (96.69%) 8 (1.47%) 8 (1.47%) 2 (0.37%)
(Continued)
TABLE E1. (Continued)
Age Component
Sensitization
No (<0.3 ISU)
Low
(0.3-1 ISU)
Medium
(1-15 ISU)
High
(>15 ISU)
Blo t 5 539 (99.26%) 1 (0.18%) 2 (0.37%) 1 (0.18%)
11 y Phl p 1 311 (67.46%) 29 (6.29%) 62 (13.45%) 59 (12.8%)
Phl p 2 378 (82%) 11 (2.39%) 46 (9.98%) 26 (5.64%)
Phl p 4 355 (77.01%) 24 (5.21%) 68 (14.75%) 14 (3.04%)
Phl p 5 336 (72.89%) 17 (3.69%) 58 (12.58%) 50 (10.85%)
Phl p 6 387 (83.95%) 18 (3.9%) 47 (10.2%) 9 (1.95%)
Phl p 7 452 (98.05%) 4 (0.87%) 2 (0.43%) 3 (0.65%)
Phl p 11 415 (90.02%) 12 (2.6%) 22 (4.77%) 12 (2.6%)
Phl p 12 436 (94.58%) 9 (1.95%) 15 (3.25%) 1 (0.22%)
Der f 1 369 (80.04%) 6 (1.3%) 63 (13.67%) 23 (4.99%)
Der f 2 362 (78.52%) 5 (1.08%) 36 (7.81%) 58 (12.58%)
Der p 1 364 (78.96%) 9 (1.95%) 64 (13.88%) 24 (5.21%)
Der p 2 366 (79.39%) 12 (2.6%) 47 (10.2%) 36 (7.81%)
Der p 10 454 (98.48%) 3 (0.65%) 3 (0.65%) 1 (0.22%)
Lep d 2 426 (92.41%) 8 (1.74%) 22 (4.77%) 5 (1.08%)
Blo t 5 452 (98.05%) 3 (0.65%) 5 (1.08%) 1 (0.22%)
Values are presented as numbers (percentages).
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TABLE E2. Percentage share of children in each timothy grass
cross-sectional sensitization profile at ages 5, 8, and 11 years
Age (y)
No
sensitization
Mild
sensitization
Moderate
sensitization
Severe
sensitization
5 85.3% (502/588) 9.9% (58/588) 4.8% (28/588) NA
8 76.8% (417/543) 8.8% (48/543) 10.3% (56/543) 4.1% (22/543)
11 68.3% (315/461) 12.4% (57/461) 9.5% (44/461) 9.8% (45/461)
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TABLE E3. Percentage share of children in each of the house dust mite cross-sectional sensitization profiles at ages 5, 8, and 11
years
Age (y) No sensitization Group 1 sensitization Group 2 sensitization
Complete moderate
sensitization
Complete high
sensitization
5 83.5% (491/588) 4.6% (27/588) 2.9% (17/588) 2.2% (13/588) 6.8% (40/588)
8 82.3% (447/543) 4.1% (22/543) 3.5% (19/543) 3.5% (19/543) 6.6% (36/543)
11 74.9% (345/461) 4.3% (20/461) 5.2% (24/461) 9.5% (44/461) 6.1% (28/461)
J ALLERGY CLIN IMMUNOL
DECEMBER 2015
1652.e8 CUSTOVIC ET AL
